Studies of HBK (I) in vitro antibacterial activity of hbk and its therapeutic efficacy on respiratory tract and urinary tract infections by intramuscular injection

HBK„ a new aminoglycoside antibiotic, was shown that is possessed a broad antimicrobial spectrum covering Gram-positive cocci and Gram-negative bacilli. Minimal inhibitory concentrations of the agent against each 20 clinical isolates of S. aureus, E. coli, K pneumoniae, S. marcescens, E. cloacae and P. aeruginosa were determined by use of MIC 2000 system. '• At a concentration of 0.39 μg/ml, HBK inhibited all the strains of S. aureus, and at a concentration of 3.13μg/ml, this drug inhibited 85, 100, 80, 80 and 70 per cent of the strains of E.coli, K. pneumoniae, S, marcescens, E. cloacae and P. aeruginosa, respectively. Ten patients suffering from respiratory tract infections and three patients of urinary tract infections received Intramuscularly 50 or 100 mg of HBK twice a day. One patient showed an excellent and nine good clinical response, while one other patient responded only fairly and other two poorly. No undeserable symptoms and signs including deafness due to administration of the drug were observed. In one case slight elevations of serum GOT and slight decrease in white blood cell count were observed, and in another case slight elevation of serum creatinine and slight elevation of serum potassium.